NASDAQ$TGTX
TG Therapeutics Inc. · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
TG Therapeutics reported strong Q2 2025 results with robust BRIUMVI revenue growth and net income.
TG Therapeutics achieved total revenue of $141.1 million in Q2 2025, driven primarily by $138.8 million in BRIUMVI product sales. The company posted net income of $28.2 million and operating income of $34.8 million, reflecting successful commercialization in the US market. R&D and SG&A expenses were $31.8 million and $55.6 million, respectively, supporting ongoing pipeline and commercial activities.
- BRIUMVI generated $138.8 million in product revenue for the quarter
- Net income reached $28.2 million with basic EPS of $0.19
- Total revenue of $141.1 million included $2.3 million from license, milestone, royalty and other sources
- Cash and cash equivalents stood at $129.1 million with total assets of $702.6 million
Headline financials
Revenue & EPS history
TG Therapeutics · Revenue · Quarterly
$141M
Revenue by segment
TG Therapeutics · $141M total across 2 segments · Q2 2025
- BRIUMVI$139M—98.4%
- License and other$2.31M—1.6%
Forward guidance
The company continues to advance BRIUMVI commercialization and pipeline development including subcutaneous formulation and azer-cel.
Tailwinds
- Strong BRIUMVI sales momentum in US and initial EU markets
- Positive long-term data from ULTIMATE studies presented
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+2.7%
Avg return
Earnings day
+5.5%
Avg return
5 days after
+4.1%
Avg return
30 days after
49%
27 / 55 earnings
Positive
+81.0%
Q3 2022
Best reaction
-49.0%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +16.3% | +19.4% | +11.1% | |
| Q4 2025 | +4.3% | -2.6% | +7.0% | |
| Q3 2025 | -1.0% | -7.3% | -9.1% | |
| Q1 2025 | -13.4% | -22.6% | -14.7% | |
| Q4 2024 | +14.4% | +27.8% | +32.3% | |
| Q3 2024 | -3.9% | +7.1% | +25.9% | |
| Q2 2024 | +16.2% | +15.7% | +24.7% | |
| Q1 2024 | +20.2% | +20.9% | +19.3% | |
| Q4 2023 | +23.8% | +28.5% | +9.3% | |
| Q3 2023 | +34.7% | +32.6% | +78.9% | |
| Q2 2023 | -49.0% | -48.2% | -49.4% | |
| Q1 2023 | +25.5% | +38.1% | +7.2% | |
| Q4 2022 | -3.8% | +7.8% | -8.2% | |
| Q3 2022 | +81.0% | +70.7% | +45.7% | |
| Q2 2022 | +19.4% | +33.4% | +9.1% | |
| Q1 2022 | -10.9% | +1.4% | -24.5% | |
| Q4 2021 | +4.7% | -11.1% | -3.6% | |
| Q3 2021 | +7.9% | +5.3% | -52.5% | |
| Q2 2021 | -27.2% | -32.8% | -15.8% | |
| Q1 2021 | -6.7% | -14.8% | -7.2% | |
| Q4 2020 | -5.0% | -3.8% | +8.8% | |
| Q3 2020 | -0.2% | +4.4% | +5.0% | |
| Q2 2020 | -12.0% | +2.6% | +22.3% | |
| Q1 2020 | +5.9% | +2.6% | -6.0% | |
| Q4 2019 | -4.1% | -13.6% | -32.6% | |
| Q3 2019 | +1.4% | +2.7% | +20.6% | |
| Q2 2019 | +3.3% | +0.1% | -8.4% | |
| Q1 2019 | -15.5% | -13.4% | -8.0% | |
| Q4 2018 | +0.4% | -8.1% | +18.2% | |
| Q3 2018 | +2.5% | -1.1% | -4.4% | |
| Q2 2018 | -3.4% | -0.4% | +0.0% | |
| Q1 2018 | -3.7% | -2.6% | +3.7% | |
| Q4 2017 | +8.5% | +10.2% | -15.1% | |
| Q3 2017 | +9.9% | +9.3% | +12.6% | |
| Q2 2017 | +1.0% | +16.0% | +22.0% | |
| Q1 2017 | +2.5% | +11.3% | +36.5% | |
| Q4 2016 | +3.4% | +22.5% | -10.6% | |
| Q3 2016 | +1.0% | +6.7% | -1.9% | |
| Q2 2016 | -7.6% | -0.2% | +13.3% | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | -6.8% | — | — | |
| Q3 2015 | +8.4% | — | — | |
| Q2 2015 | -2.2% | — | — | |
| Q1 2015 | -6.0% | — | — | |
| Q3 2014 | +14.6% | — | — | |
| Q1 2012 | -3.7% | — | — | |
| Q2 2012 | -14.3% | — | — | |
| Q4 2011 | -23.0% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +36.4% | — | — | |
| Q4 2010 | +7.7% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro